Hoya Vision Care announced in a press release interim 6-month clinical evidence from a randomized controlled clinical trial evaluating the safety and efficacy of Miyosmart iQ spectacle lenses, the company’s novel myopia control solution that builds on its Defocus Incorporated Multiple Segments (DIMS) Technology, now with Triple Enhanced Design (DIMS TED), in children aged 4-12 with progressive myopia.  

According to the company, the data show no myopia progression on average at 6 months, with minimal eye growth in children wearing Miyosmart iQ spectacle lenses, and twice the effectiveness of Miyosmart spectacle lenses in controlling axial elongation and myopia progression, based on interim clinical evidence.

In addition, design changes like a smaller clear central zone, higher defocus power, and extended treatment zone—in addition to positioning defocus segments closer to the center—are intended to continuously activate the nearperipheral retina, identified as the region most responsive to myopic defocus. Higher defocus power enables a stronger myopic defocus signal, and an extended treatment zone with more defocus segments ensures extensive coverage of the child’s peripheral visual field, even for larger frames, the company reports.  

Miyosmart iQ is currently available in major eye hospitals across China, with plans to continue the roll-out throughout 2026, Miyosmart iQ will be sold alongside Hoya Vision Care’s Miyosmart spectacle lenses, the company says.

According to Hoya Vision Care, the findings are based on interim data and should not be interpreted as long-term outcomes. In addition, the Miyosmart and Miyosmart iQ spectacle lenses have not been approved for use in the management of myopia in all countries and are not currently available for sale in all countries, including the United States. OM